Bluejay Diagnostics (NASDAQ:BJDX) Raised to “Sell” at Wall Street Zen

Bluejay Diagnostics (NASDAQ:BJDX) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bluejay Diagnostics has an average rating of “Sell”.

Bluejay Diagnostics Stock Up 11.5%

Shares of NASDAQ:BJDX opened at $1.45 on Friday. The company’s fifty day moving average is $2.64 and its two-hundred day moving average is $2.44. Bluejay Diagnostics has a 12-month low of $1.03 and a 12-month high of $16.68. The company has a market cap of $1.49 million, a P/E ratio of -0.12 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Insider Activity at Bluejay Diagnostics

In related news, major shareholder Financial Lp Hrt purchased 64,047 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were acquired at an average cost of $1.51 per share, with a total value of $96,710.97. Following the completion of the purchase, the insider owned 126,993 shares of the company’s stock, valued at $191,759.43. The trade was a 101.75% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. 18.47% of the stock is owned by hedge funds and other institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.